IL106540A - Crystalline amifostine compositions and methods for the preparation and use of same - Google Patents

Crystalline amifostine compositions and methods for the preparation and use of same

Info

Publication number
IL106540A
IL106540A IL10654093A IL10654093A IL106540A IL 106540 A IL106540 A IL 106540A IL 10654093 A IL10654093 A IL 10654093A IL 10654093 A IL10654093 A IL 10654093A IL 106540 A IL106540 A IL 106540A
Authority
IL
Israel
Prior art keywords
present
compositions
crystalline
preparation
methods
Prior art date
Application number
IL10654093A
Other languages
English (en)
Other versions
IL106540A0 (en
Original Assignee
Us Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26795942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL106540(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/099,298 external-priority patent/US5424471A/en
Application filed by Us Bioscience filed Critical Us Bioscience
Publication of IL106540A0 publication Critical patent/IL106540A0/xx
Publication of IL106540A publication Critical patent/IL106540A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Organic Insulating Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Sub-Exchange Stations And Push- Button Telephones (AREA)
IL10654093A 1992-07-31 1993-07-30 Crystalline amifostine compositions and methods for the preparation and use of same IL106540A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92292992A 1992-07-31 1992-07-31
US08/099,298 US5424471A (en) 1992-07-31 1993-07-29 Crystalline amifostine compositions and methods of the preparation and use of same

Publications (2)

Publication Number Publication Date
IL106540A0 IL106540A0 (en) 1994-08-26
IL106540A true IL106540A (en) 2000-02-17

Family

ID=26795942

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10654093A IL106540A (en) 1992-07-31 1993-07-30 Crystalline amifostine compositions and methods for the preparation and use of same

Country Status (22)

Country Link
US (1) US5591731A (es)
EP (1) EP0655917B1 (es)
JP (1) JP3503943B2 (es)
CN (2) CN1070370C (es)
AT (1) ATE261729T1 (es)
AU (1) AU681858B2 (es)
CA (1) CA2120133C (es)
CZ (1) CZ284417B6 (es)
DE (1) DE69333453T2 (es)
DK (1) DK0655917T3 (es)
ES (1) ES2215992T3 (es)
HU (1) HU227122B1 (es)
IL (1) IL106540A (es)
IS (1) IS1843B (es)
MX (1) MX9304627A (es)
NO (2) NO309636B1 (es)
NZ (1) NZ255182A (es)
PL (1) PL178463B1 (es)
PT (1) PT655917E (es)
RU (1) RU2125880C1 (es)
SG (1) SG47101A1 (es)
SK (1) SK283318B6 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051563A (en) 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US6573253B2 (en) 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6017922A (en) 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
US6407278B2 (en) 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
DE10043170C2 (de) * 2000-09-01 2002-10-24 Klinge Co Chem Pharm Fab Amifostin-Monohydrat und Verfahren zu seiner Herstellung
CN1148192C (zh) * 2000-10-19 2004-05-05 南京振中生物工程有限公司 细胞保护剂氨磷汀制剂及其制备方法
US7053072B2 (en) 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US7629333B2 (en) * 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
CN1305478C (zh) * 2004-05-12 2007-03-21 天津市资福医药科技开发有限公司 氨磷汀冻干制剂及其制备方法
JP5038912B2 (ja) 2005-02-16 2012-10-03 アナコール ファーマシューティカルズ，インコーポレイテッド ホウ素含有小分子
US7767657B2 (en) 2005-02-16 2010-08-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2007047315A1 (en) * 2005-10-20 2007-04-26 Albemarle Corporation Amifostine dihydrate crystalline composition
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
NZ570257A (en) 2006-02-16 2011-11-25 Anacor Pharmaceuticals Inc Boron-containing small molecules as anti-inflammatory agents
US20090239817A1 (en) * 2006-04-17 2009-09-24 Goverment Of The United States Of America, As Represented By The Secretary, Dept Of Health Organic thiophosphate antiretroviral agents
US9585849B2 (en) * 2006-04-17 2017-03-07 The Burlington Hc Research Group, Inc. Broad spectrum antiviral and methods of use
WO2008060441A2 (en) * 2006-11-09 2008-05-22 Scidose Llc Stable amifostine liquid concentrate
BRPI0908565A2 (pt) 2008-03-06 2017-05-23 Anacor Pharmaceuticals Inc composto, formulação farmacêutica, métodos para reduzir a liberação de uma citocina ou de uma quimiocina, para tratar uma condição em um animal e para inibir uma fosfodiesterase
US20100256092A1 (en) * 2008-05-12 2010-10-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CN101412732B (zh) * 2008-09-02 2011-09-07 大连美罗药业股份有限公司 三水合3-氨基丙基胺乙基硫代磷酸高纯稳定晶体及其制备方法
CN101347412B (zh) * 2008-09-02 2011-07-27 大连美罗药业股份有限公司 三水合氨磷汀结晶冻干制剂及其制备方法
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2348863A4 (en) * 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
US9493489B2 (en) * 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
MX2011006334A (es) * 2008-12-17 2011-09-22 Anacor Pharmaceuticals Inc Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c] [1,2]-oxaborol-1-ol.
KR20130031233A (ko) * 2009-07-28 2013-03-28 아나코르 파마슈티칼스 인코포레이티드 삼치환된 붕소 함유 분자
AP4039A (en) 2009-08-14 2017-02-28 Daitao Chen Boron-containing small molecules as antiprotozoal agents
MX2012002031A (es) * 2009-08-19 2012-07-04 Anacor Pharmaceuticals Inc Moleculas pequeñas que contienen boro como agentes antiprotozoarios.
WO2011037731A1 (en) * 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Boron containing small molecules
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US20110212918A1 (en) * 2009-11-11 2011-09-01 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011062614A1 (en) * 2009-11-20 2011-05-26 Tonix Pharmaceuticals, Inc. Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
WO2011094450A1 (en) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Boron-containing small molecules
AP2012006482A0 (en) 2010-03-19 2012-10-31 Anacor Pharmacueticals Inc Boron-containing small molecules as anti-protozoalagent
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
SG10201507032YA (en) 2010-09-07 2015-10-29 Anacor Pharmaceuticals Inc Benzoxaborole derivatives for treating bacterial infections
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
TWI432204B (zh) * 2011-06-03 2014-04-01 Taiwan Hopax Chems Mfg Co Ltd 對抗自由基的醫藥組合物
CN102286020A (zh) * 2011-07-11 2011-12-21 大连美罗大药厂 一水合3-氨基丙基胺乙基硫代磷酸的制备方法
NZ747040A (en) 2013-03-15 2020-02-28 Tonix Pharmaceuticals Inc Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
CA2915708C (en) * 2013-06-18 2018-02-06 Aminomedix Inc. Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids
SG11201701995PA (en) 2014-09-18 2017-04-27 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
CN114306208A (zh) * 2014-10-02 2022-04-12 西托索尔本茨公司 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗的用途
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
AU2018383098B2 (en) 2017-12-11 2024-12-12 Tonix Pharma Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN110735176B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备配位化合物单晶或无定型物的方法
CN110607552B (zh) * 2018-10-30 2024-02-20 中国科学院化学研究所 一种利用水溶液制备单晶或无定型物的方法
CN110606868A (zh) * 2018-10-30 2019-12-24 中国科学院化学研究所 一种制备多肽或蛋白质单晶或无定型物的方法
WO2020088480A1 (zh) * 2018-10-30 2020-05-07 中国科学院化学研究所 一种利用溶液冻结制备单晶或无定型物的方法
CN110607551B (zh) * 2018-10-30 2024-02-20 中国科学院化学研究所 一种制备食品添加剂单晶或无定型物的方法
CN110616463B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备有机半导体分子单晶或无定型物的方法
CN118267895A (zh) * 2018-10-30 2024-07-02 中国科学院化学研究所 一种制备药物或药物中间体无定型物的方法
EP3824880A1 (en) * 2019-11-25 2021-05-26 Clevexel Pharma Freeze-dried powder containing 2-[(3-aminopropyl)amino]ethanethiol and its use for preparing a thermogel
KR20240041506A (ko) * 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법
CN115957190A (zh) * 2023-01-09 2023-04-14 开封明仁药业有限公司 一种注射用氨磷汀及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) * 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
JPS6041676B2 (ja) * 1977-09-21 1985-09-18 山之内製薬株式会社 Ｓ−２−（３−アミノプロピルアミノ）エチルジハイドロジエンホスホロチオエ−ト１水和結晶の新規製法
US4424216A (en) * 1979-07-31 1984-01-03 The Rockefeller University Method for the reduction of mucin viscosity
DE3586845T2 (de) * 1984-08-08 1993-04-01 Survival Technology Absorptionsverbesserer.
EP0473673A4 (en) * 1989-05-24 1995-05-17 Us Bioscience Method for protection from azt side effects and toxicity

Also Published As

Publication number Publication date
PL178463B1 (pl) 2000-05-31
CZ23095A3 (en) 1995-10-18
SG47101A1 (en) 1998-03-20
EP0655917A1 (en) 1995-06-07
IL106540A0 (en) 1994-08-26
EP0655917A4 (en) 1995-08-02
AU681858B2 (en) 1997-09-11
CN1070370C (zh) 2001-09-05
NZ255182A (en) 1996-12-20
ES2215992T3 (es) 2004-10-16
IS4060A (is) 1994-02-01
CN1092980A (zh) 1994-10-05
HUT70191A (en) 1995-09-28
HU227122B1 (en) 2010-07-28
CN1146428C (zh) 2004-04-21
RU2125880C1 (ru) 1999-02-10
NO5775A (no) 1995-03-22
DE69333453T2 (de) 2005-01-27
DE69333453D1 (de) 2004-04-22
IS1843B (is) 2003-01-30
NO20005775D0 (no) 2000-11-15
CA2120133C (en) 1998-06-09
NO309636B1 (no) 2001-03-05
PT655917E (pt) 2004-08-31
MX9304627A (es) 1994-04-29
DK0655917T3 (da) 2004-07-26
ATE261729T1 (de) 2004-04-15
AU4796693A (en) 1994-03-03
SK283318B6 (sk) 2003-05-02
EP0655917B1 (en) 2004-03-17
US5591731A (en) 1997-01-07
HK1010692A1 (en) 1999-06-25
JP3503943B2 (ja) 2004-03-08
CN1307870A (zh) 2001-08-15
NO950343D0 (no) 1995-01-30
NO950343L (no) 1995-03-22
CA2120133A1 (en) 1994-02-17
HU9500277D0 (en) 1995-03-28
NO315691B1 (no) 2003-10-13
CZ284417B6 (cs) 1998-11-11
SK11395A3 (en) 1995-07-11
PL307298A1 (en) 1995-05-15
JPH08500104A (ja) 1996-01-09

Similar Documents

Publication Publication Date Title
SG47101A1 (en) Crystalline amifostine compositions and methods for the preparation and use of same
MY110631A (en) Crystalline amifostine compositions and methods for the preparation and use of same.
CA2227887A1 (en) Pharmaceutical compositions of conjugated estrogens and methods for their use
ES8603870A1 (es) Un procedimiento para la preparacion de derivados de 2,2'-iminobisetanol.
HUT68498A (en) L-dopa ester compositions and process to prepare them
ZA9711606B (en) Cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them.
NO178697C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive pyrazolopyridin-forbindelser
EP0373758A3 (en) Antiseptic compositions containing hexahydro-5-pyrimidinamine compounds and thymol and a process for their preparation
IL102814A0 (en) Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them
FI894899A0 (fi) Menetelmä dispergoituvan kiinteän lääkeainekoostumuksen valmistamiseksi
TW427906B (en) Antifungal compositions
UA74388C2 (uk) Фармацевтичні композиції тизоксаніду і нітазоксаніду
ZA979647B (en) Heterocyclic compounds, compositions and uses.
AU711128C (en) Anti-helicobacter pylori compositions containing 1-methylcarbapenem derivatives as the active ingredient
HU895241D0 (en) Process for the preparation of substituted 1,3,5-triazin-trione derivatives and pharmaceutical compositions containing said compounds as active ingredient
HUT50821A (en) Process for producing new ester derivatives of acyclovir and pharmaceutical compositions comprising such compound
ZA979650B (en) Heterocyclic compounds, compositions and uses.
DE60031557D1 (de) Steroide, ihre herstellung , pharmazeutische zusammensetzungen mit ihnen und verwendungen dieser verbindungen
EP0382635A3 (fr) Utilisation de dérivés d'alkyl-5 pyridazine comme médicaments actifs sur le système cholinergique
HUT56716A (en) Process for producing pharmaceutical compositions suitable for preventing and treating autoimmune illnesses and skin diseases caused by heat and light radiation
BG106093A (en) 14beta-h-sterols, pharmaceutical compositions comprising them and the use of these derivatives for the preparation of meiosis regulating medicaments
IT1272762B (it) Derivati benz/e/indenici farmaceuticamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
GEP20002241B (en) Polymorphs and Hydrated Forms of Lesopitron Dichlorohydrate, Methods for Its Preparation and Pharmaceutical Compositions Containing Same
ITMI912324A0 (it) Derivati dall'acido beta-idrossibutirrico, procedimento per la loro preparazione e relative composizioni farmaceutiche
IT1248525B (it) Derivati dell'eseridina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HC Change of name of proprietor(s)
KB Patent renewed
KB20 Patent renewed for 20 years
MM9K Patent not in force due to non-payment of renewal fees